Oppenheimer Downgrades Legend Biotech to Perform, Lowers Price Target to $40

Benzinga · 2d ago
Oppenheimer analyst Trevor Allred downgrades Legend Biotech (NASDAQ:LEGN) from Outperform to Perform and lowers the price target from $75 to $40.